Mountford, Paul A.
Leiphrakpam, Premila D.
Weber, Hannah R.
McCain, Andrea
Scribner, Robert M.
Scribner, Robert T.
Duarte, Ernesto M.
Chen, Jie
Noe, Dragana
Borden, Mark A.
Buesing, Keely L. http://orcid.org/0000-0002-8461-1938
Funding for this research was provided by:
Air Force Surgeon General (FA4600-12-D-9000)
National Heart, Lung, and Blood Institute (R01HL151151)
Article History
Received: 20 December 2022
Accepted: 2 May 2023
First Online: 26 June 2023
Declarations
:
: All animal experiments were approved and supervised by the University of Nebraska-Lincoln Institutional Animal Care and Use Committee.
: Not applicable.
: Authors PAM, RMS, RTS, MAB, and KLB have financial holdings in the company Respirogen, Inc. in the form of stock and stock option agreements. MAB is a Founder and Chief Scientific Officer of Respirogen, Inc. Respirogen, Inc. looks to commercialize the oxygen microbubble technology.